Boehringer Ingelheim completes $36 million investment in Laval for state-of-the-art research centre

New facility dedicated to finding treatments for serious infectious diseases

28-May-2008

Boehringer Ingelheim completed a $36 million investment in new laboratories in Laval, Quebec, designed to support research into treatments for serious infectious diseases. The new facility will allow Boehringer Ingelheim to hire 40 additional high-calibre scientists who will join an existing team of 150 researchers.

As one of the four principal research centers for Boehringer Ingelheim worldwide, the Laval facility focuses on the discovery of new treatments for Hepatitis C and the human immunodeficiency virus (HIV, which causes AIDS) infection, diseases for which either no vaccine exists or current therapy is unsatisfactory. The new laboratories will allow Boehringer Ingelheim to continue to contribute to and complement its existing product portfolio, which includes HIV treatments VIRAMUNE(R) and APTIVUS(R).

"We are glad to see how the Laval facility will increase its capacities for playing an important role in the company's global research network of four major and three support sites," stated Dr. Andreas Barner, Vice-Chairman of the Board of Managing Directors and Head of Corporate Board Division Pharma Research, Development and Medicine, Boehringer Ingelheim. "We are drawing upon talent here in Quebec and Canada to discover and develop medicines that will help in the fight against the growing problem of infectious virological diseases around the world, in particular Hepatitis C and HIV infection."

In 2007, Boehringer Ingelheim invested close to $100 million in research and development in Canada with close to $50 million in Laval and the remainder in medical clinical trials.

https://www.bionity.com/en/news/82625/boehringer-ingelheim-completes-36-million-investment-in-laval-for-state-of-the-art-research-centre.html